// App-Quantinova.ai

978 : Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus

Researchers

Presenter

  • Muhammad Shipa

Principal Investigators

  • liliana ribeiro santos

  • Dao X Nguyen

  • Andrew Embleton-Thirsk

  • Mariea parvaz

  • David Isenberg

  • Caroline Gordon

  • Michael Ehrenstein

Medical Centers

  • Kings College London, London, United Kingdom

  • University College London, London, UK

  • Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom

Locations

  • Brazil

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Belimumab

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved